Nature Article Cites Cleanascite™ to Investigate Serum Lipid Factors Linking Ageing and Cancer
By: Biotech Support Group
Gomes, Ana P., et al. "Age-induced accumulation of methylmalonic acid promotes tumour progression."
The risk of cancer and associated mortality increases substantially in humans from the age of 65 years onwards. The authors describe how metabolic alterations that occur with age can produce a systemic environment that favors the progression of tumors. Specifically, that methylmalonic acid (MMA), a by-product of propionate metabolism, is upregulated in the serum of older people and functions as a mediator of tumor progression. To support this analysis, the authors state "HS (human serum) samples were manipulated to assess the components … that might facilitate entrance of MMA into cells. To delipidate the HS, Cleanascite Lipid Removal Reagent (Biotech Support Group) was used according to the manufacturer's protocol …, using a 1:4 volume ratio of Cleanascite reagent to sample". The authors conclude that depletion of lipidic structures from serum taken from an older population, resulted in a reduction in total serum MMA levels and was sufficient to abrogate the pro-aggressive phenotype. The data show that MMA, complexed with lipidic structures, is a circulatory factor that contributes to the pro-aggressive effects of ageing in cancer cells and is sufficient to drive tumor progression and aggressiveness. Thus, MMA is a promising therapeutic target for advanced carcinomas.
"Its rewarding to see another reference whereby Cleanascite™
To download whitepaper entitled "Cleanascite™
For more information visit: Cleanascite™
About Biotech Support Group LLC
Converging with cultural and technological disruptions forthcoming in healthcare, Biotech Support Group develops methods for cost effective and efficient sample prep essential for these expanding markets. Following a tiered business strategy, the company continues its growth in the consumable research products area supporting the rapidly expanding installation of LC-MS instrument and computational infrastructure.
For Business Development, contact: Matthew Kuruc 732-274-2866, firstname.lastname@example.org
Biotech Support Group LLC